- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Gemtuzumab ...
MedChemExpress - Model Gemtuzumab ozogamicin -220578-59-6
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML)[1][2].MCE products for research use only. We do not sell to patients.
Gemtuzumab ozogamicin
MCE China:Gemtuzumab ozogamicin
Brand:MedChemExpress (MCE)
Cat. No.HY-109539
CAS:220578-59-6
Purity:98.0%
Storage:-80°C, protect from light
Shipping:Shipping with dry ice.
Description:Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML).
In Vitro:Gemtuzumab ozogamicin (1-250 ng/mL ; 72 hours) has cell cytotoxicity in CD33-positive cells[1]. Gemtuzumab ozogamicin is an ADC. After binding of the antibody to CD33 and subsequent internalization, Calicheamicin mediates cytotoxicity to CD33-positive myeloid cells primarily through induction of DNA damage and subsequent apoptosis[1].
Hot selling product:Ixazomib citrate | Dipyridamole | Vorasidenib | GSK2334470 | Erythromycin | GSK621 | Mulberroside A | BCI | PEG2000-DSPE | Lichenase
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022 Apr 1;150(7):1141-1155. [Content Brief]
[2]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。
